Biogen Inc vs Global X Robo Global Robotics & Automation ETF — how do they compare? Biogen Inc trades at $191.4 (market cap $30.86B), while Global X Robo Global Robotics & Automation ETF trades at $81.01. Which is the better fit depends on your goals.
| BIIB | ROBO | |
|---|---|---|
Market Cap | $30.86B | — |
Sector | Health | Sector/Thematic |
52-Week High | $216.63 | $90.34 |
52-Week Low | $122.68 | $60.15 |
Enterprise Value | $33.14B | — |
Trailing returns across standard periods
Latest headlines on both assets
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →